An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Quidel Corporation (NASDAQ: QDEL) announced its participation in the Raymond James 43rd Annual Institutional Investors Conference on March 9, 2022, at 10:25 a.m. ET in Orlando, Florida. CEO Douglas Bryant and CFO Randy Steward will present insights on the company's business and financial developments, followed by a Q&A session. A live webcast will be available through Quidel's Investor Relations website, with a replay accessible for 14 days post-event. Quidel is recognized for its diagnostic solutions and rapid testing technologies, enhancing global healthcare.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James & Associates 43rd Annual Institutional Investors Conference to be held at the J.W. Marriott Orlando Grande Lakes hotel in Orlando, Florida on Wednesday, March 9, 2022 at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time).
Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on March 9th with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.
A live webcast and audio archive of the presentation will be available via the Investor Relations section of the company’s website at http://ir.quidel.com or by clicking the link below.
Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com.
